Emerging Trends and Translational Challenges in Drug and Vaccine Delivery, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 3905

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Avenue, CPB 325, Oklahoma City, OK 73117, USA
Interests: biomaterials; biologics; long-term drug delivery; nanomedicine; hydrogels; ocular; inner ear
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Vaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
Interests: vaccine; human vaccines; vaccine development; formulation development; attenuated vaccine; viral vaccines; bacterial vaccines; subunit vaccines; pediatric vaccines; COVID vaccines; measles and rubella vaccines; rotavirus vaccine; HPV vaccine; Shigella vaccine; Salmonella vaccine; combination vaccines; polio vaccine; stability study; potency assay; analytical assays; preclinical study; immunogenicity study; biophysical characterization; adjuvants; scale-up; technology transfer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug and vaccine delivery are continuously progressing, and the developments in the past several decades have been enormous. Novel therapeutic modalities leverage advancements in long-term effects, controlled release, cocktail therapies, combinatorial methods, self-administration, and improved patient adherence by rationally designing innovative approaches for drug and vaccine delivery. Given the emerging trends and challenges, the comprehensive preclinical assessment of drug and vaccine delivery systems includes mechanistic chemistry, physicochemical characterizations, pre-formulation investigations, molecular pharmacology, and biological and toxicological evaluations. A better understanding of in vivo behavior, as well as the in vitro–in vivo characterization cascade of safety and efficacy testing, is needed to accelerate the translational challenges in developing a drug product from the proof-of-concept stage to scale-up issues, reproducibility, manufacturing, and commercialization processes. This Special Issue aims to provide the readers with the recent advancements in drug and vaccine delivery and associated challenges from bench to clinic and reflects on the pharma-/biotech- industrial applications. Research and review manuscripts focused on this theme are welcomed.

We look forward to receiving your contributions.

Dr. Vibhuti Agrahari
Dr. Prashant Kumar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomaterials and polymer chemistry
  • novel drug delivery designs
  • sustained/controlled release
  • vaccine delivery systems
  • DNA and gene vaccine delivery
  • delivery of mRNA vaccines
  • biomedical applications
  • development of 3D/organoids models to study delivery system
  • in vivo imaging techniques for drug delivery system
  • application of microfluidics, QbD, and PAT approaches in manufacturing, as well as scale-up techniques

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3372 KiB  
Article
Poly(acrylic acid)/Poly(vinyl alcohol) Microarray Patches for Continuous Transdermal Delivery of Levodopa and Carbidopa: In Vitro and In Vivo Studies
by Yaocun Li, Lalitkumar K. Vora, Jiawen Wang, Akmal Hidayat Bin Sabri, Andrew Graham, Helen O. McCarthy and Ryan F. Donnelly
Pharmaceutics 2024, 16(5), 676; https://doi.org/10.3390/pharmaceutics16050676 - 17 May 2024
Viewed by 3494
Abstract
Levodopa (LD) has been the most efficacious medication and the gold standard therapy for Parkinson’s disease (PD) for decades. However, its long-term administration is usually associated with motor complications, which are believed to be the result of the fluctuating pharmacokinetics of LD following [...] Read more.
Levodopa (LD) has been the most efficacious medication and the gold standard therapy for Parkinson’s disease (PD) for decades. However, its long-term administration is usually associated with motor complications, which are believed to be the result of the fluctuating pharmacokinetics of LD following oral administration. Duodopa® is the current option to offer a continuous delivery of LD and its decarboxylase inhibitor carbidopa (CD); however, its administration involves invasive surgical procedures, which could potentially lead to lifelong complications, such as infection. Recently, dissolving microarray patches (MAPs) have come to the fore as an alternative that can bypass the oral administration route in a minimally invasive way. This work explored the potential of using dissolving MAPs to deliver LD and CD across the skin. An acidic polymer poly(acrylic acid) (PAA) was used in the MAP fabrication to prevent the potential oxidation of LD at neutral pH. The drug contents of LD and CD in the formulated dissolving MAPs were 1.82 ± 0.24 and 0.47 ± 0.04 mg/patch, respectively. The in vivo pharmacokinetic study using female Sprague–Dawley® rats (Envigo RMS Holding Corp, Bicester, UK) demonstrated a simultaneous delivery of LD and CD and comparable AUC values between the dissolving MAPs and the oral LD/CD suspension. The relative bioavailability for the dissolving MAPs was calculated to be approximately 37.22%. Accordingly, this work highlights the use of dissolving MAPs as a minimally invasive approach which could potentially bypass the gastrointestinal pathway and deliver both drugs continuously without surgery. Full article
Show Figures

Figure 1

Back to TopTop